GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $3,331,172.92 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 35,506 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the completion of the transaction, the chief financial officer now directly owns 2,472 shares in the company, valued at approximately $231,923.04. The trade was a 93.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Stock Down 7.4 %

WGS traded down $7.19 on Friday, hitting $89.38. 725,309 shares of the company were exchanged, compared to its average volume of 909,701. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock's fifty day moving average is $78.01 and its 200-day moving average is $53.19. The company has a market cap of $2.46 billion, a PE ratio of -28.74 and a beta of 2.02. GeneDx Holdings Corp. has a 12 month low of $2.85 and a 12 month high of $98.87.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm's revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.82) EPS. Equities research analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on WGS. TD Cowen boosted their target price on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday. Wells Fargo & Company boosted their price objective on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Finally, Craig Hallum boosted their price target on GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, GeneDx presently has an average rating of "Moderate Buy" and a consensus price target of $70.67.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock worth $2,214,000 after purchasing an additional 44,889 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of GeneDx in the third quarter valued at approximately $604,000. Franklin Resources Inc. bought a new stake in GeneDx in the 3rd quarter valued at $301,000. Tidal Investments LLC bought a new position in GeneDx during the third quarter worth $514,000. Finally, Barclays PLC increased its holdings in shares of GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company's stock valued at $803,000 after purchasing an additional 14,681 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.